Back to results
US 11,078,539 B2Granted
Detecting colorectal neoplasm
AssigneesMayo Foundation for Medical Education and Research, Exact Sciences Development Company, LLC
InventorsDavid A. Ahlquist, William R. Taylor, Douglas W. Mahoney, Graham P. Lidgard, Hatim T. Allawi
Life of this patent
Estimating the term…
Abstract
Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as colorectal cancer.
Claims13
A method comprising:
- extracting genomic DNA from a biological sample of a human individual suspected of having or having colorectal cancer,
- treating the extracted genomic DNA with bisulfite,
- amplifying the bisulfite-treated genomic DNA using primers specific for two to eleven different markers, wherein one of the two to eleven different markers is selected from ankyrin repeat domain 33B (ANKRD33B), leucine-rich repeat-containing protein 4 (LRRC4), protein phosphatase 2 regulatory subunit (PPP2R5C), and zinc finger protein 568 (ZNF568), wherein if LRRC4 is one of the two to eleven different markers than at least one of ANKRD33B, PPP2R5C, and ZNF568 must be one of the two to eleven different markers,
- wherein amplifying the bisulfite-treated genomic DNA using primers specific for a CpG site for ANKRD33B is a set of primers that specifically binds at least a portion of a genetic region comprising chromosome 5:10565042-10565191 or chromosome 5:10564655-10564807,
- wherein amplifying the bisulfite-treated genomic DNA using primers specific for a CpG site for LRRC4 is a set of primers that specifically binds at least a portion of a genetic region comprising 7:127671918-127672318,
- wherein amplifying the bisulfite-treated genomic DNA using primers specific for a CpG site for ZNF568 is a set of primers that specifically binds at least a portion of a genetic region comprising 19:37407197-37407365,
- wherein amplifying the bisulfite-treated genomic DNA using primers specific for a CpG site for PPP2R5C is a set of primers that specifically binds at least a portion of a genetic region comprising 14:102248062-102248216,
- measuring the methylation level of the CpG site for the two to eleven different markers by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, or bisulfite genomic sequencing PCR.
5 more elements
A method comprising:
- extracting genomic DNA from a biological sample of a human individual suspected of having or having colorectal cancer,
- treating the extracted genomic DNA with bisulfite,
- amplifying the bisulfite-treated genomic DNA using primers specific for two to eleven different markers, wherein one of the two to eleven different markers is selected from ankyrin repeat domain 33B (ANKRD33B), protein phosphatase 2 regulatory subunit (PPP2R5C), and zinc finger protein 568 (ZNF568),
- wherein amplifying the bisulfite-treated genomic DNA using primers specific for a CpG site for ANKRD33B is a set of primers that specifically binds at least a portion of a genetic region comprising chromosome 5:10565042-10565191 or chromosome 5:10564655-10564807,
- wherein amplifying the bisulfite-treated genomic DNA using primers specific for a CpG site for ZNF568 is a set of primers that specifically binds at least a portion of a genetic region comprising 19:37407197-37407365,
- wherein amplifying the bisulfite-treated genomic DNA using primers specific for a CpG site for PPP2R5C is a set of primers that specifically binds at least a portion of a genetic region comprising 14:102248062-102248216,
- measuring the methylation level of the CpG site for the two to eleven different markers by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, or bisulfite genomic sequencing PCR.
4 more elements
Dependencies are inferred from the claim text.